rs10117876 - TUBB4BP6 - BRINP1
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial - Unknown journal (n.d.) · Unknown authors · PubMed 28763429
ABSTRACT: Objectives The major clinical side-effect of the ERBB2 targeted breast cancer therapy, trastuzumab, is a decline in left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity. Methods The NCCTG N9831 trial compared adjuvant doxorubicin and cyclophosphamide followed by either weekly paclitaxel (Arm A); paclitaxel then trastuzumab (Arm B); or concurrent paclitaxel and trastuzumab (Arm C) in patients with HER2-positive breast cancer. A GWAS was performed on all patients with available DNA (N=1,446). We used linear regression to identify SNPs associated with decline in LVEF, adjusting for age, baseline LVEF, anti-hypertensive medications and the first two principle components. Results 618,863 SNPs passed quality co
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
BRINP1 cardiotoxicity risk before trastuzumab therapy Moderate
rs10117876 associates with increased LVEF decline during trastuzumab and chemotherapy in HER2+ breast cancer patients.
Discuss with oncologist if diagnosed with HER2+ breast cancer; arrange baseline cardiac imaging.